Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.

被引：0
|
作者：
Shah, Payal D. [1 ]
Zarrin, Haley [1 ]
Wethington, Stephanie [2 ]
Latif, Nawar [1 ]
Martin, Lainie [1 ]
Rodriguez, Diego [1 ]
Elkins, Katie [1 ]
Giuntoli, Robert [1 ]
Burger, Robert [1 ]
Tanyi, Janos [1 ]
Morgan, Mark [1 ]
Domchek, Susan M. [1 ]
Gailliard, Stephanie [2 ]
Armstrong, Deborah K. [2 ]
Simpkins, Fiona [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A72
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [2] Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Morgan, Mark Aloysuis
    Torigian, Drew A.
    Pagan, Cheyenne
    Rodriguez, Diego
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Le-Ming
    Smith, Simon
    Dean, Emma
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Simpkins, Fiona
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] The combination of intravenous bevacizumab and metronomic oral cyclophosphamide for recurrent platinum-resistant ovarian cancer.
    Barber, Emma L.
    Neubauer, Nikki Lynn
    Zsiros, Emese
    Schink, Julian C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] ATR Inhibitors in Platinum-Resistant Ovarian Cancer
    Li, Siyu
    Wang, Tao
    Fei, Xichang
    Zhang, Mingjun
    [J]. CANCERS, 2022, 14 (23)
  • [5] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [6] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)
    Simpkins, Fiona
    Nasioudis, Dimitrios
    Wethington, Stephanie L.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Torigian, Drew A.
    Omran, Dalia K.
    Rodriguez, Diego
    Smith, Simon
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei-Ting
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Giuntoli, Robert Lawrence, II
    Liu, Joyce F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Platinum-gemcitabine-bevacizumab (PGA) for platinum-resistant/refractory recurrent ovarian cancer.
    Niu, Jiaxin
    Kundranda, Madappa N.
    Weiss, Glen J.
    Farley, John H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer.
    Oldenburg, Jan
    Normann, Marius
    Turzer, Martin
    Solheim, Olesya
    Diep, Lien My
    Gajdzik, Beata
    Rud, Erik
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
    Cannistra, S. A.
    Matulonis, U.
    Penson, R.
    Wenham, R.
    Armstrong, D.
    Burger, R. A.
    Mackey, H.
    Douglas, J.
    Hambleton, J.
    McGuire, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 257S - 257S
  • [10] Capecitabine in treatment of platinum-resistant recurrent ovarian cancer
    Boehmer, C
    Jaeger, W
    [J]. ANTICANCER RESEARCH, 2002, 22 (1A) : 439 - 443
12345